Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo

Dafeng Yang, Christina M. Torres, Kankana Bardhan, Mary Zimmerman, Tracy L. McGaha, Kebin Liu

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The death receptor Fas and its physiological ligand (FasL) regulate apoptosis of cancerous cells, thereby functioning as a critical component of the host cancer immunosurveillance system. To evade Fas-mediated apoptosis, cancer cells often downregulate Fas to acquire an apoptosis-resistant phenotype, which is a hallmark of metastatic human colorectal cancer. Therefore, targeting Fas resistance is of critical importance in Fas-based cancer therapy and immunotherapy. In this study, we demonstrated that epigenetic inhibitors decitabine and vorinostat cooperate to upregulate Fas expression in metastatic human colon carcinoma cells. Decitabine also upregulates BNIP3 and Bik expression, whereas vorinostat decreased Bcl-x L expression. Altered expression of Fas, BNIP3, Bik, and Bcl-x L resulted in effective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis. Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis. Analysis of tumor-bearing lung tissues revealed that a large portion of tumor-infiltrating CD8 + T cells are FasL +, and decitabine and vorinostat-mediated tumor-suppression efficacy was significantly decreased in Fas gld mice compared with wild-type mice, suggesting a critical role for FasL in decitabine and vorinostat-mediated tumor suppression in vivo. Consistent with their function in apoptosis sensitization, decitabine and vorinostat significantly increased the efficacy of CTL adoptive transfer immunotherapy in an experimental metastasis mouse model. Thus, our data suggest that combined modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL immunotherapy is an effective approach for the suppression of colon cancer metastasis.

Original languageEnglish (US)
Pages (from-to)4441-4449
Number of pages9
JournalJournal of Immunology
Volume188
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

decitabine
Fas Ligand Protein
Colon
Apoptosis
Carcinoma
Neoplasms
Neoplasm Metastasis
Immunotherapy
Up-Regulation
Adoptive Immunotherapy
Immunologic Monitoring
Death Domain Receptors
Adoptive Transfer
vorinostat
In Vitro Techniques
Epigenomics
Colonic Neoplasms

ASJC Scopus subject areas

  • Immunology

Cite this

Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo. / Yang, Dafeng; Torres, Christina M.; Bardhan, Kankana; Zimmerman, Mary; McGaha, Tracy L.; Liu, Kebin.

In: Journal of Immunology, Vol. 188, No. 9, 01.05.2012, p. 4441-4449.

Research output: Contribution to journalArticle

Yang, Dafeng ; Torres, Christina M. ; Bardhan, Kankana ; Zimmerman, Mary ; McGaha, Tracy L. ; Liu, Kebin. / Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo. In: Journal of Immunology. 2012 ; Vol. 188, No. 9. pp. 4441-4449.
@article{76455522c60a4412a8977257bb103f32,
title = "Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo",
abstract = "The death receptor Fas and its physiological ligand (FasL) regulate apoptosis of cancerous cells, thereby functioning as a critical component of the host cancer immunosurveillance system. To evade Fas-mediated apoptosis, cancer cells often downregulate Fas to acquire an apoptosis-resistant phenotype, which is a hallmark of metastatic human colorectal cancer. Therefore, targeting Fas resistance is of critical importance in Fas-based cancer therapy and immunotherapy. In this study, we demonstrated that epigenetic inhibitors decitabine and vorinostat cooperate to upregulate Fas expression in metastatic human colon carcinoma cells. Decitabine also upregulates BNIP3 and Bik expression, whereas vorinostat decreased Bcl-x L expression. Altered expression of Fas, BNIP3, Bik, and Bcl-x L resulted in effective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis. Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis. Analysis of tumor-bearing lung tissues revealed that a large portion of tumor-infiltrating CD8 + T cells are FasL +, and decitabine and vorinostat-mediated tumor-suppression efficacy was significantly decreased in Fas gld mice compared with wild-type mice, suggesting a critical role for FasL in decitabine and vorinostat-mediated tumor suppression in vivo. Consistent with their function in apoptosis sensitization, decitabine and vorinostat significantly increased the efficacy of CTL adoptive transfer immunotherapy in an experimental metastasis mouse model. Thus, our data suggest that combined modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL immunotherapy is an effective approach for the suppression of colon cancer metastasis.",
author = "Dafeng Yang and Torres, {Christina M.} and Kankana Bardhan and Mary Zimmerman and McGaha, {Tracy L.} and Kebin Liu",
year = "2012",
month = "5",
day = "1",
doi = "10.4049/jimmunol.1103035",
language = "English (US)",
volume = "188",
pages = "4441--4449",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo

AU - Yang, Dafeng

AU - Torres, Christina M.

AU - Bardhan, Kankana

AU - Zimmerman, Mary

AU - McGaha, Tracy L.

AU - Liu, Kebin

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The death receptor Fas and its physiological ligand (FasL) regulate apoptosis of cancerous cells, thereby functioning as a critical component of the host cancer immunosurveillance system. To evade Fas-mediated apoptosis, cancer cells often downregulate Fas to acquire an apoptosis-resistant phenotype, which is a hallmark of metastatic human colorectal cancer. Therefore, targeting Fas resistance is of critical importance in Fas-based cancer therapy and immunotherapy. In this study, we demonstrated that epigenetic inhibitors decitabine and vorinostat cooperate to upregulate Fas expression in metastatic human colon carcinoma cells. Decitabine also upregulates BNIP3 and Bik expression, whereas vorinostat decreased Bcl-x L expression. Altered expression of Fas, BNIP3, Bik, and Bcl-x L resulted in effective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis. Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis. Analysis of tumor-bearing lung tissues revealed that a large portion of tumor-infiltrating CD8 + T cells are FasL +, and decitabine and vorinostat-mediated tumor-suppression efficacy was significantly decreased in Fas gld mice compared with wild-type mice, suggesting a critical role for FasL in decitabine and vorinostat-mediated tumor suppression in vivo. Consistent with their function in apoptosis sensitization, decitabine and vorinostat significantly increased the efficacy of CTL adoptive transfer immunotherapy in an experimental metastasis mouse model. Thus, our data suggest that combined modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL immunotherapy is an effective approach for the suppression of colon cancer metastasis.

AB - The death receptor Fas and its physiological ligand (FasL) regulate apoptosis of cancerous cells, thereby functioning as a critical component of the host cancer immunosurveillance system. To evade Fas-mediated apoptosis, cancer cells often downregulate Fas to acquire an apoptosis-resistant phenotype, which is a hallmark of metastatic human colorectal cancer. Therefore, targeting Fas resistance is of critical importance in Fas-based cancer therapy and immunotherapy. In this study, we demonstrated that epigenetic inhibitors decitabine and vorinostat cooperate to upregulate Fas expression in metastatic human colon carcinoma cells. Decitabine also upregulates BNIP3 and Bik expression, whereas vorinostat decreased Bcl-x L expression. Altered expression of Fas, BNIP3, Bik, and Bcl-x L resulted in effective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis. Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis. Analysis of tumor-bearing lung tissues revealed that a large portion of tumor-infiltrating CD8 + T cells are FasL +, and decitabine and vorinostat-mediated tumor-suppression efficacy was significantly decreased in Fas gld mice compared with wild-type mice, suggesting a critical role for FasL in decitabine and vorinostat-mediated tumor suppression in vivo. Consistent with their function in apoptosis sensitization, decitabine and vorinostat significantly increased the efficacy of CTL adoptive transfer immunotherapy in an experimental metastasis mouse model. Thus, our data suggest that combined modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL immunotherapy is an effective approach for the suppression of colon cancer metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84860327244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860327244&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1103035

DO - 10.4049/jimmunol.1103035

M3 - Article

C2 - 22461695

AN - SCOPUS:84860327244

VL - 188

SP - 4441

EP - 4449

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -